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Background: Postmenopausal osteoporosis is a chronic disease requiring long-term treatment. Strontium 
ranelate (SrRan) 2g/day has proven efficacy against vertebral and non vertebral fractures including hip over 5 
years in postmenopausal women. Results showing the continuous benefit on osteoporotic fractures and bone 
mineral density (BMD) over 8 years have already been reported (1). 
Objectives: This abstract presents efficacy results over 10 years. 
Methods: The two double blind placebo-controlled phase III studies included a total of 6740 Caucasian women 
with postmenopausal osteoporosis. In SOTI, patients were randomly assigned to receive SrRan 2g/day or 
placebo for 4 years and during the 5th year, half of the SrRan group continued with SrRan. In TROPOS, patients 
were randomly assigned to receive SrRan 2g/day or placebo for 5 years. Patients having participated in both 
studies up to 5 years were invited to enter a 3-year open-label extension study, subsequently extended by 2 
years, and then received strontium ranelate up to 10 years. Here are presented the efficacy results in patients 
treated with SrRan for 10 years. 
Results: At SOTI and TROPOS baseline, patients treated for 10 years (n=233) had a profile similar to the whole 
population with a mean (SD) age of 72.0 (5.5) years, a mean (SD) lumbar spine and femoral neck BMD T-score 
of –3.30 (1.38) and –2.95 (0.57) respectively. Over the 10-year period, lumbar BMD increased continuously and 
significantly (p<0.05 up to year 10) with, at 10 years, a relative change from baseline of 34.5%±20.2. At the 
femoral neck and total hip sites, the BMD increased significantly until year 7, with a relative change from baseline 
of 10.7%±12.1 and 11.7%±13.6 respectively, and then remained stable. 
The cumulative incidences of new vertebral and non vertebral fractures (20.6% and 13.7% respectively) over the 
5-year extension were not statistically different (p=1.00 and 0.672 respectively) to the cumulative incidences over 
the 5 years in the original studies (18.5% and 12.9% respectively). To assess the anti-fracture efficacy of SrRan in 
the absence of placebo group, we searched for a matching population in the placebo group of TROPOS using the 
10-year probability of major osteoporotic fracture calculated with FRAX® as matching variable. The mean 10-year 
probability of major osteoporotic fracture, calculated with FRAX®, in the 233 patients treated for 10 years with 
SrRan was 25.8% at the time of their inclusion in the extension study. The incidences of vertebral and non-
vertebral fracture observed over the 5 years of TROPOS were significantly higher (p<0.05) in the matching 
placebo group than those observed in the ''10-year'' population over the 5- year extension, with a relative risk 
reduction with SrRan of 35% and 38% for vertebral fractures and non-vertebral fractures respectively. 
Strontium ranelate remained safe and well tolerated over 10 years with no unexpected adverse event. 
Conclusions: These results are in favour of the maintenance of the efficacy of strontium ranelate over 10 years, 
with a good safety profile. 
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